Answers are grounded in this paper and cite their sources.
We developed and validated a novel ECL based sandwich immunoassay for the NfL protein in serum (NfL(Umea47:3)); levels in ALS were more than 20-fold higher than in controls. Our data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.
No takes yet. Share an insight, caveat, or question.
Gaiottino et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: